| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(5 months ago) | |
|
US6790837 (Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(6 days from now) | |
Rebetol is owned by Schering.
Rebetol contains Ribavirin.
Rebetol has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Rebetol are:
- US6790837
Rebetol was authorised for market use on 29 July, 2003.
Rebetol is available in solution;oral dosage forms.
The generics of Rebetol are possible to be released after 05 October, 2023.
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Treatment: NA
Dosage: SOLUTION;ORAL
More Information on Dosage
REBETOL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic